These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 16796779

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.
    Owen RG, Hillmen P, Rawstron AC.
    Clin Lymphoma; 2005 Mar; 5(4):278-81. PubMed ID: 15794865
    [Abstract] [Full Text] [Related]

  • 3. CD52 is a molecular target in advanced systemic mastocytosis.
    Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, Cerny-Reiterer S, Gleixner KV, Walz C, Hoetzenecker K, Müllauer L, Reiter A, Sotlar K, Sexl V, Valent P, Mayerhofer M.
    FASEB J; 2014 Aug; 28(8):3540-51. PubMed ID: 24760752
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
    Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M.
    Blood; 2011 Jul 14; 118(2):276-81. PubMed ID: 21566092
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S.
    Cancer; 2006 Jun 15; 106(12):2645-51. PubMed ID: 16688777
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.
    Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP.
    Ann Oncol; 2006 Aug 15; 17(8):1275-82. PubMed ID: 16788002
    [Abstract] [Full Text] [Related]

  • 9. CD52 expression in hairy cell leukemia.
    Quigley MM, Bethel KJ, Sharpe RW, Saven A.
    Am J Hematol; 2003 Dec 15; 74(4):227-30. PubMed ID: 14635201
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.
    Nucl Med Biol; 2008 Jul 15; 35(5):599-604. PubMed ID: 18589304
    [Abstract] [Full Text] [Related]

  • 11. Targeting CD40 in Waldenström's macroglobulinemia.
    Lee M, Advani R.
    Clin Lymphoma Myeloma; 2009 Mar 15; 9(1):87-9. PubMed ID: 19362983
    [Abstract] [Full Text] [Related]

  • 12. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL.
    Clin Cancer Res; 2006 Dec 01; 12(23):7174-9. PubMed ID: 17145843
    [Abstract] [Full Text] [Related]

  • 13. CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
    Rawstron AC, Laycock-Brown G, Hale G, Davies FE, Morgan GJ, Child JA, Hillmen P, Owen RG.
    Haematologica; 2006 Nov 01; 91(11):1577-8. PubMed ID: 17043027
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of CD52 in peripheral T-cell lymphoma.
    Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA.
    Haematologica; 2007 Apr 01; 92(4):566-7. PubMed ID: 17488672
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R.
    Pediatr Blood Cancer; 2005 Mar 01; 44(3):251-4. PubMed ID: 15390358
    [Abstract] [Full Text] [Related]

  • 18. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
    Turner MJ, Lamorte MJ, Chretien N, Havari E, Roberts BL, Kaplan JM, Siders WM.
    J Neuroimmunol; 2013 Aug 15; 261(1-2):29-36. PubMed ID: 23759318
    [Abstract] [Full Text] [Related]

  • 19. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, Herndlhofer S, Streubel B, Rabitsch W, Sperr WR, Mayerhofer M, Rülicke T, Valent P.
    Clin Cancer Res; 2014 Jul 01; 20(13):3589-602. PubMed ID: 24799522
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.